NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ --  Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced the appointment of Matthew Buten to the role of Chief Financial Officer (CFO) effective by December 20, 2021, following the retirement of CFO James Engelhart.

Matt Buten is on Penn Health-Tech's Strategic Advisory Board. Learn more on his new role at Biohaven Read more